Four years of early benefit assessment of new drugs in Germany: a qualitative study on methodological requirements for quality of life data
Crossref DOI link: https://doi.org/10.1007/s10198-016-0765-6
Published Online: 2016-02-02
Published Print: 2017-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Blome, Christine
Augustin, Matthias
Metin, Hidayet
Lohrberg, David
Funding for this research was provided by:
Janssen-Cilag GmbH, Neuss, Germany
Text and Data Mining valid from 2016-02-02